I have been a researcher in BioSciences for more than 25 years at INRAE (French National Research Institute for Agriculture, Food and Environment) where I led a fundamental research team in the field of virology. From 2016, I trained in entrepreneurship and technology transfer issues to promote a (global) patent and secret know-how from INRAE and the University of Grenoble. in order to design and then market innovative vaccines. Thus, in October 2019, I co-founded the company AIOVA, a biotech that designs latest-generation vaccines (DNA-type vaccines), with high added value for its pharmaceutical industry customers and with unique properties. AIOVA vaccines provide multi-strain immunity (so-called universal vaccines) and a long-lasting immunity (several years). AIOVA is dedicated to the fight against emerging or re-emerging and deadly pandemics such as AIDS and influenza and has recently been mobilized to fight against the SARS-COV-2, the causal agent of the COVID-19.